iRadimed Corporation IRMD
85.76
0.56
0.66%
as of 25 Sep
- Market cap
- $1.1B
- P/E
- 47.1×
Follow IRMD
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
23.31% | 24.78% | 25.04% | 23.52% | |
| 20.28% | 21.71% | 21.85% | 20.82% | ||
ROIC |
37.14% | 37.60% | 41.46% | 40.36% | |
Return on Tangible Assets |
22.09% | 23.69% | 23.96% | 22.65% | |
Average Days of Receivables |
62.83 | 59.52 | 56.75 | 55.77 | |
Free Cash Flow per Share |
1.10 | 1.30 | 1.88 | 1.92 | |
Free Cash Flow |
13.95 | 16.53 | 23.97 | 24.55 | |
Capital Expenditures |
(11.06) | (8.42) | (4.97) | (2.59) | |
Piotroski F-Score |
3.00 | 5.00 | 5.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
16.15% | 17.11% | 18.69% | 16.87% | |
Accounts Receivable Turnover |
6.65 | 6.92 | 6.61 | 7.16 | |
Accounts Payable Turnover |
9.89 | 10.49 | 8.38 | 11.11 | |
Inventory Turnover |
1.61 | 1.77 | 1.78 | 1.78 | |
Average Days of Payables |
46.14 | 34.08 | 39.85 | 32.39 | |
Days of Inventory on Hand |
232.05 | 217.61 | 217.01 | 214.68 | |
Tax Rate |
(0.21) | (0.21) | (0.22) | (0.22) | |
Research and Development Expense of Revenue |
3.41% | 3.55% | 3.83% | 3.58% | |
Selling, General and Administrative Expense of Revenue |
42.79% | 42.00% | 40.61% | 40.37% | |
Share Based Compensation of Revenue |
3.58% | 3.48% | 3.22% | 3.30% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.18 | 1.11 | 1.23 | 1.18 | |
Depreciation/Fixed assets |
0.04 | 0.05 | 0.06 | 0.07 | |
Capex/Depreciation |
(11.28) | (7.22) | (3.48) | (1.59) | |
Revenue per Share |
6.33 | 6.59 | 6.75 | 6.75 | |
Operating CF per Share |
1.97 | 1.96 | 2.26 | 2.12 | |
Capex per Share |
(0.87) | (0.66) | (0.39) | (0.20) | |
Capex to Sales |
0.14 | 0.10 | 0.06 | 0.03 | |
Net Profit Margin |
26.31% | 26.82% | 27.36% | 26.70% |
Columns are period end dates